The pharmacokinetics and urinary excretion of nine glycopeptide antibiotics with diverse pls (3.8 to 8.5) and lipophilicities were studied. The disposition of the aridicin antibiotics and their hydrolysis products were examined in male CD-1 mice after subcutaneous and intravenous administration and compared with the disposition of teicoplanin, ristocetin, and vancomycin. The total systemic clearance, half-life, volume of distribution, and urinary excretion were highly correlated with pIs. In general, as the pI decreased, the clearance, urinary recovery, and volume of distribution decreased, whereas the half-life increased. With those glycopeptides that had similar pIs, clearance decreased and half-life increased with increasing lipophiicity. The urinary recovery of the glycopeptides decreased with decreasing pI and increasing lipophilicity. Because vancomycin (pI = 8.0) is cleared by glomerular filtration, increased binding to serum is the likely mechanism of reduced renal clearance for glycopeptides with low pls. These results are consistent with previous findings concerning the correlation of physical-chemical properties and the drug disposition of small organic molecules. Results of these studies also indicate that desirable pharmacokinetic properties can be incorporated into glycopeptides through semisynthetic modifications.
The pharmacokinetics and distribution of most pharmacological agents have a dramatic influence on their therapeutic utility and duration of action (4, 11) . In the case of antimicrobial agents, the physical-chemical properties associated with long durations of action have been examined only in a few cases. The beta-lactam antibiotics with negatively charged side chains in the 3 position, as exemplified by cefonicid (1) and ceftriaxone (2) , have long half-lives in serum. Increased serum protein binding decreases the renal clearance of these compounds and extends their half-lives (4, 11) . In the case of the sulfonamide antibacterial agents, detailed structure-pharmacokinetic studies have been performed (14) . In rats, the rate constant of elimination, renal clearance, and nonrenal clearance of the sulfonamides decrease with increasing lipophilicity and increasing acidity (i.e., increased negative charge). This decrease in renal and nonrenal clearance is partially explained by increased binding to serum. The effects of charge and lipophilicity on the pharmacokinetics of larger molecules have been largely neglected due to the paucity of useful agents with molecular weights in excess of 700. With products of recombinant DNA technology emerging as potential drugs, information on the influence of physical-chemical factors on the disposition of the larger peptidelike molecules is becoming particularly important.
The recent increase in methicillin-resistant, gram-positive bacteria has caused an increase in the use of vancomycin, a glycopeptide antibiotic with a molecular weight of 1,447. We have recently described the discovery, isolation, and characterization of the aridicins, novel glycopeptide antibiotic products of Kibdelosporangium aridum (SK&F AAD216). These antibiotics differ from vancomycin in that they have a lipid acyl side chain and a net negative charge at neutral pHs the n-decanoyl moiety. Although these analogs differ from aridicin A by one or two additional methylene units, they are remarkably more lipophilic (16) . A series of hydrolysis products were generated to alter the charge and lipophilicity of aridicin A (Sitrin et al., submitted). Pseudoaglycone A is a product of aridicin A that lacks the mannose subunit and, thus, has a similar charge but increased lipophilicity. The mannosyl aglycone lacks the glycolipid subunit, a change which alters both charge and lipophilicity. The aridicin aglycone lacks both the mannose and the glycolipid. The analogs and control compounds that were studied varied in their pIs by four pH units, from 3.8 to 8.5 (16; Sitrin et al., submitted; Table 1 ). The aridicins and their partial degradation products are active against staphylococci in vitro (Sitrin et al., submitted), and as also reported for the teicoplanin series (12) , the aglycone is the most active molecular species in vitro.
The results of previous prophylaxis experiments in laboratory infection studies indicate that the aridicins and their hydrolysis products have long durations of action (6) . In (8) .
Antibiotic assays. Antibiotic activity in serum was evaluated by disk agar diffusion with penicillin assay agar that was seeded with a Bacillus subtilis ATCC 6633 spore suspension as the indicator. Serum samples were evaluated against standards diluted in mouse serum. Assays were incubated overnight at 30°C. Although the precision of the assay methods was not tested for each antibiotic, the coefficient of variation of this general procedure was 6 to 10%. It is well known that the attached peptide nucleus is required for microbiological activity of glycopeptides (7, 20, 21) . Degra-
RESULTS
The absorption and elimination of vancomycin and the aridicin hydrolysis products mannosyl aglycone and aridicin aglycone were relatively rapid after subcutaneous administration (Fig. 2) . However, after subcutaneous administration of aridicins A, B, and C and pseudoaglycone A, the serum concentrations increased with time for 180 to 240 min, indicating slow absorption from the injection site. This slow absorption phase resulted in diminished peak concentrations and increased residence times of the glycopeptides in the body. Thus, subcutaneous administration decreased the acute apparent in vivo potency but extended the duration of action of these glycopeptides. The data obtained after subcutaneous dosing provide information on the antibiotic concentrations in serum under conditions used in mouse protection studies reported previously (6) .
Because of the slow absorption after subcutaneous administration, intravenous administration was utilized to obtain detailed pharmacokinetic data and to determine the influence of elimination rate (half-life) on the duration of action of these compounds. The serum concentrations of the aridicins, the aridicin A hydrolysis products, vancomycin, teicoplanin, and ristocetin following intravenous administration are shown in Fig. 3 sponding clearances and steady-state volumes of distribution were lower. It should be noted that for the aridicins, a considerable portion of the area under the curve was obtained by extrapolation ( Table 1) .
The recovery of antibacterial activity in urine was determined after subcutaneous and intravenous administration. The urinary recovery of antibiotic activity from 0 to 6 h was, in general, higher after intravenous than subcutaneous administration. In general, as the pI of the antibiotics decreased, the urinary recovery also decreased. For the glycopeptides with long half-lives in serum, the low urinary recovery was in part due to the short collection periods of urine. Nevertheless, these data indicate that the urinary elimination of the antibiotics decreased with decreasing pl.
Because the aglycone derivatives of the aridicins and teicoplanin are known to have higher in vitro potency, several urine and serum samples were analyzed by HPLC to check for bioconversion (loss of carbohydrates). No measurable levels of aglycone derivatives were observed for the aridicins, teicoplanin, or vancomyin. These results indicate that the microbiological assay measured only parent drug.
DISCUSSION
The clearances and half-lives of glycopeptide antibiotics are highly correlated with their pIs. In general, as pI decreases, the clearance and volume of distribution decrease, whereas the half-life increases. The decrease in clearance is much greater than the decrease in volume of distribution, causing a large increase in half-life with decreasing pl. The urinary recovery data for 0 to 6 h (Table 2) indicate that the decrease in total systemic clearance is at least partially due to a reduced rate of renal clearance. Thus, a decrease in the pl appears to result in a reduction in the renal clearance of these glycopeptides. Changes in the pI alone do not explain all of the observed differences in the pharmacokinetics of these compounds. Reverse-phase HPLC data for aridicins A, B, and C (16; Sitrin et al., submitted) indicate that lipophilicity increases as the length of the lipid chain increases. For these compounds which have identical pls, the clearance decreased and the half-life increased with increasing lipophilicity.
In some cases, a considerable portion of the area under the curve was obtained by extrapolation (Table 1 ). This may have caused errors in the estimates of the pharmacokinetic parameters. Therefore, the reported pharmacokinetic parameters for the aridicins should be considered tentative. However, if a second and longer elimination phase was missed due to insufficient sampling, the calculated clearances would be overestimated and the steady-state volumes of distribution and mean residence times would be underestimated. Because the glycopeptides with the longest half- lives and lowest clearances had the greatest portion of the area under the curve extrapolated, this possible error may have artificially decreased the differences between the pharmacokinetics of these glycopeptides. Nevertheless, the overall correlation of physical-chemical and pharmacokinetic parameters with these glycopeptides was not altered by this possible error. Quantitative structure-pharmacokinetic relationships in animals and humans have been reported for only a few classes of drugs (9, 13, 14, 17) . In general, lipophilichydrophilic and electronic properties are far more important than steric characteristics in governing the overall pharmacokinetic behavior of drugs. It is well known that positively charged drugs display low binding to serum and negatively charged drugs exhibit high binding to serum (4, 11) . It is also known that increases in drug lipophilicity generally are associated with increases in serum binding (4, 11) . Increased binding to serum decreases the fraction of drug available for drug elimination (decreased renal filtration) and can thus decrease drug clearance. The effect of charge on drug distribution (volume of distribution) depends on the relative effect of charge on drug binding to serum and tissue proteins. Because vancomycin is renally cleared by glomerular filtration and the urinary recovery of the aridicins is low, the observed low renal clearance of the aridicins is consistent with increased binding to serum with decreased pl. Increased binding to serum could also explain the trend toward a smaller volume of distribution with decreasing pl. Differences in the pharmacokinetics of glycopeptides with similar pls may be explained by differences in lipophilicity. As the lipophilicity of the aridicins (A < B < C) increases, clearance decreases and half-life increases. This hypothesis is consistent with previous findings concerning the correlation of physical-chemical properties and drug disposition of small organic molecules (4, 11) . Studies in which the binding of an extensive series of glycopeptides to serum are being examined are in progress to examine this hypothesis.
Results of this study demonstrate that the aridicins and their partial hydrolysis products have much longer half-lives than vancomycin and ristocetin. The aridicins, but not their hydrolysis products, have half-lives longer than that of teicoplanin. The fact that teicoplanin has a long half-life in humans and animals (18, 19) suggests that the results of these studies in mice may be useful in predicting the pharmacokinetics in humans. Thus, the aridicins and their hydrolysis products may have long half-lives in humans. The strong correlation between pharmacokinetics and physicalchemical properties, with serum protein binding being the likely basis of this correlation, indicates that desirable pharmacokinetic properties can be incorporated into glycopeptides through semisynthetic modifications. These findings are the first report of the correlation of physicalchemical properties with the disposition of large peptidelike molecules.
